Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously.
Calendar
–
View all events & presentations
Events.
Oct
06
2026
Virtual KOL Event: Multi-Nodal Inhibition for the Treatment of Endometrial Cancer
Latest
–
View all news
News and updates.
Sep 08 2026
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026
AUSTIN, Texas --(BUSINESS WIRE)--Sep. 8, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October
Read More
Sep 01 2026
Faeth Therapeutics to Participate in Upcoming September Investor Conferences
AUSTIN, Texas --(BUSINESS WIRE)--Sep. 1, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor
Read More
Aug 28 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas --(BUSINESS WIRE)--Aug. 28, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company’s common stock in connection with their
Read More
Aug 17 2026
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration — Faeth expects topline data from its ongoing Phase 2 trial in
Read More
Aug 14 2026
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments
Appointments reinforce technical operations and investor engagement as the company advances its clinical programs AUSTIN, Texas --(BUSINESS WIRE)--Aug. 14, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations,
Read More